SureTrader Nadex Advertisement Interactive Brokers Advertisement SureTrader
Home > Boards > US Listed > Medical - Drugs >

RXI Pharmaceuticals Corp (RXII)

RXII RSS Feed
Add RXII Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 5/19/2017 9:45:57 AM - Followers: 145 - Board type: Free - Posts Today: 0

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform.  Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to "silence," or down-regulate, the expression of a specific gene that may be overexpressed in a disease condition.  Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXi's first RNAi product candidate, RXI-109, entered into RXi's first human clinical trial in 2012.  RXI-109 targets connective tissue growth factor (CTGF), a key regulatory of fibrosis and scar formation, and is initially being developed to reduce or inhibit scar formation in the skin following surgery.
 

 



RXi Pharmaceuticals Corp., has received patent approval for their new experimental breast cancer vaccine which became part of the company's arsenal after acquiring Apthera Inc. in April of this year.
The specific patents in question regard using the vaccine NeuVax with the drug Herceptin which is used in women to slow the production of the HER2 protein in tumors, while NeuVax attempts to make the body's immune system fight off cancerous cells.
According to The Telegram:
"The patents also cover using NeuVax in patients not eligible for Herceptin treatment."
With their patent in place the company plans to begin human tests in early 2012.
According to RXi the patents were developed by Dr. George E. Peoples, director of the Cancer Vaccine Development Program for the U.S. Military Cancer Institute and RXi is leasing the patents for their own work.
 

 



This May, RXi Pharmaceuticals Corp. observed two momentous events: The biotechnology company completed its spinoff from Galena Biopharma Inc., and Dr. Geert Cauwenbergh took the helm as president and chief executive officer. The small company's first product, an anti-scarring medication called RXI-109, entered clinical trials this year, and is based on the pioneering work in RNA interference of RXi scientific founder and Nobel Laureate Dr. Craig C. Mello. Dr. Cauwenbergh came to RXi after a long career in pharmaceuticals, most recently as president and chief executive officer of a company he founded, Barrier Therapeutics. What attracted you to come to Worcester? "It was the technology, well, the technology and the chemistry with these people. They're very bright." As a publicly traded company, how do you reconcile the needs of the investors, which are sometimes a short-term desire for profits, with the needs of medical research, which sometimes takes years? "Through business development. Basically what you do as a small biotech is you try to create a big network with people who have interest in various stages of development. ... In two or three years they get antsy and they want to cash in, but at that point in time there will be and there is already a network of business development contacts in place where you can for instance get nondiluted money without having to raise money and go back to the stock market and shareholders by making regional deals or geographic deals ...

NEWS

June 9, 2015 RXi Pharmaceuticals Strengthens Intellectual Property Portfolio for Novel RNAi Platform

http://finance.yahoo.com/news/rxi-pharmaceuticals-strengthens-intellectual-property-110200033.html

Dec 17, 2014 RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301

http://finance.yahoo.com/news/rxi-pharmaceuticals-announces-sustained-effect-120200746.html

Press Releases
RXi Pharmaceuticals to Present at Biotech Showcase™ 2013 - December 19, 2012
RXi Pharmaceuticals Announces Initiation of Second Double-Blind Vehicle Controlled Phase 1 Study With Its Anti-Scarring Compound, RXI-109 - December 5, 2012
RXi Pharmaceuticals Announces Pharmacokinetic Results of its Single Dose Phase 1 Study with RXI-109 in Healthy Volunteers - November 15, 2012
RXi Pharmaceuticals Reports Financial Results for the Third Quarter of 2012 - November 14, 2012
RXi Pharmaceuticals to Present at 12th Annual Biotech Symposium - October 16, 2012
RXi Pharmaceuticals Awarded NCI SBIR Funding to Advance Self-Delivering RNAi Technology - October 4, 2012
RXi Pharmaceuticals to Present at 11th Annual BIO Investor Forum - October 2, 2012
RXi Pharmaceuticals Announces Completion of Dosing in Phase 1 Trial for RXI-109 Program - September 24, 2012
RXi Pharmaceuticals Reports Financial Results for the Second Quarter of 2012 - August 15, 2012
RXi Pharmaceuticals Appoints Jeannette Graf MD and Leroy Young MD to its Scientific Advisory Board - July 13, 2012
 
Share Statistics
Avg Vol (3 month)3: 215,443
Avg Vol (10 day)3: 145,371
Shares Outstanding5: 338m
Float: 53.34M
% Held by Insiders1: 9.01%
% Held by Institutions1: 0.50%
 



http://www.rxipharma.com/

 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RXII
Current Price
Volume:
Bid Ask Day's Range
News News Alert: PCI Biotech and RXi Pharmaceuticals Extend Research Collaboration to the Field of Immuno-oncology 05/22/2017 07:05:00 AM
PostSubject
#4475   Typical fluff from a failing entity. RS Full Contact Yoga 05/19/17 09:45:57 AM
#4474   1) Anyone take note that the RXI-231 (skin-lightener) sabaidii2 05/12/17 01:11:09 PM
#4473   No. It happens to be consistent. Probably The Other Guy 05/12/17 01:01:23 PM
#4472   My point is, it's part of scheduled stock Full Contact Yoga 05/12/17 12:30:29 PM
#4471   No. They are open market purchases. Not bought The Other Guy 05/12/17 12:12:15 PM
#4470   He's receiving the shares, monthly, he's not the Full Contact Yoga 05/12/17 11:37:29 AM
#4469   Um, reread the filings please. The Other Guy 05/12/17 11:32:33 AM
#4468   Geert nor any other insider are buying, they're Full Contact Yoga 05/12/17 11:10:40 AM
#4467   Thanks TOG...appreciate the info. the submariner 05/12/17 07:21:18 AM
#4466   Brief but good cc. Geert strongly opposes RS. The Other Guy 05/11/17 05:23:13 PM
#4465   I'm in same boat, but I'm sticking it out. senderos 05/09/17 11:54:23 AM
#4464   I was in at .65 and may be the submariner 05/09/17 11:33:36 AM
#4463   Still the same old POS i see,lol the submariner 05/05/17 10:58:08 AM
#4462   GLTY!! senderos 05/04/17 04:30:21 PM
#4461   Me too at .61 simmons420 05/04/17 02:57:28 PM
#4460   Well, I'm tripling down today at .61. senderos 05/04/17 02:16:06 PM
#4459   You're reading my mind, plenty of trade opps Full Contact Yoga 05/04/17 09:38:04 AM
#4458   It is a relatively low float. That is The Other Guy 05/04/17 09:28:02 AM
#4457   I agree that the dilution needs to stop. The Other Guy 05/04/17 09:21:25 AM
#4456   Buy low sell high I'm showing 18 million simmons420 05/04/17 09:09:30 AM
#4455   We have 2 conferences next week. With data simmons420 05/04/17 08:55:14 AM
#4454   The RS will get approved, no doubt. The Full Contact Yoga 05/04/17 08:35:06 AM
#4453   The shareholders meeting is approved rs for 2017? cary73 05/04/17 07:50:39 AM
#4452   Thanks FCY. Sounds about right. senderos 05/03/17 12:22:25 PM
#4451   At a minimum, the OS is 22,045,481, likely Full Contact Yoga 05/03/17 12:16:26 PM
#4450   I am having trouble determining the OS here. senderos 05/03/17 12:01:39 PM
#4449   Been out of this a few years going the submariner 05/02/17 02:30:06 PM
#4448   RS is definitely negative to shareholders...the best vote Full Contact Yoga 05/01/17 10:27:11 AM
#4447   Interesting. I have Fidelity and I see the The Other Guy 04/28/17 09:35:00 AM
#4446   Fidelity shows 16.1% institutional ownership, and insider ownership senderos 04/28/17 09:25:47 AM
#4445   I will give you the institutions. There is The Other Guy 04/28/17 09:02:30 AM
#4444   Exactly. senderos 04/28/17 08:31:37 AM
#4443   If RXI can not apply for extension and BioPharma 04/28/17 08:20:05 AM
#4442   Voting yes allows RS as a possibility. The The Other Guy 04/28/17 07:56:33 AM
#4441   This is part requirement for RXI to apply BioPharma 04/27/17 10:04:32 PM
#4440   Proxy is out. I am voting against RS. The Other Guy 04/27/17 07:18:43 PM
#4439   Yes, yes, we know. You should really go The Other Guy 04/26/17 06:39:05 PM
#4438   I'll give credit to Geert as he's been sabaidii2 04/26/17 06:24:30 PM
#4437   Geert makes his regularly scheduled purchase. Must be The Other Guy 04/26/17 04:43:37 PM
#4436   The pre 14A covers the listing issue, vote Full Contact Yoga 04/24/17 10:37:13 AM
#4435   Is RXI going to get a 6-month waiver sabaidii2 04/20/17 12:54:41 PM
#4434   I remember it as the desire of not sabaidii2 04/20/17 12:51:59 PM
#4433   I may be mistaken, but I thought the The Other Guy 04/20/17 12:43:08 PM
#4432   Today's press release says RXI-185 (reducing skin laxity) sabaidii2 04/20/17 10:39:25 AM
#4431   RXI-231: Consumer testing will initiate in May 2017 sabaidii2 04/20/17 09:34:37 AM
#4430   RXi Pharmaceuticals to Present an Update on its The Other Guy 04/20/17 07:22:33 AM
#4429   You are correct. I misspoke. I senderos 04/19/17 07:10:48 PM
#4428   What insider buying? Geert's buys are all under sabaidii2 04/19/17 05:50:13 PM
#4427   IMO, for weeks I have thought there was senderos 04/19/17 05:29:40 PM
#4426   Hmmm, interesting last half hour. Probably another The Other Guy 04/19/17 04:15:28 PM
PostSubject